Thank you for the question.
CADTH, the Canadian Agency for Drugs and Technologies in Health. I believe the member is referring to that line. And I'm very pleased, Mr. Chair, to be able to speak to that agency. As its name implies, it's a joint federally, provincially, territorially supported agency.
There was a sense a number of years ago, when I was the provincial health deputy, that there were economies of scale, looking at some of these new technologies one time, to gather the expertise and then share that among the provinces and territories. They do drug assessments. They do medical device assessments and other things.
One of the challenges we faced in the last number of years was a shortage of medical isotopes. What we learned through that period was that there are a number of ways, through good information sharing and working together.... Provinces coped with that shortage and actually worked very hard--positions on the front line.... We did a good deal of coordination as well to try to effectively make sure that patients were not harmed as different kinds of responses, different isotopes in some cases and different procedures in others, were used during that situation.
As part of this, we have given a grant, an increase, of $3 million to CADTH over two years--some of it is reflected in this year's budget--to do some follow-up work on isotopes, to make sure we learn the lessons, in a sense, that we're looking forward to the new technologies: what do we understand from what we learned in that experience, and how do we share those lessons? Some parts of the country did things differently from others. Who had the best outcomes? Can we understand that? And also, to work internationally, do a piece of research essentially on what is our best way going forward.
Again, we felt it was a positive experience. We wanted to make sure we learned the lessons and assessed that experience. That's why there's an increase in the CADTH budget.